Company Profile
Mereo BioPharma Stock Price, News & Analysis
- Ticker:
- MREO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
0.31 USD (+2.42%)
Close
Last updated: July 28, 2026
54.2M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, MREO closed up 2.42% at $0.3094. No new same-company headline was identified in the current news window.
Company overview
Business overview
Mereo BioPharma is a rare-disease and immunology company focused on precision therapies for underserved conditions. Its business is built around a concentrated pipeline and value creation through clinical execution.
Geographic Base and Sector Classification
Headquartered in the United Kingdom and listed on NASDAQ as an ADR, Mereo has a global specialty-biopharma profile.
Business Model Characteristics
The company depends on clinical data, pipeline prioritization, and the ability to build a durable orphan-disease story.
Position Within the Biotechnology Landscape
Mereo is a small-cap rare-disease name whose valuation is closely tied to proof-of-concept and strategy.
Future catalysts
Mereo’s catalysts are setrusumab and the osteogenesis imperfecta program, plus any rare-disease update that extends the platform. The market will care about whether the company can keep pushing into a meaningful orphan-disease niche.
Recent news
- 01
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Source: Mereo BioPharma
- 02
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Source: Mereo BioPharma
- 03
Mereo BioPharma Provides Corporate Update
Source: Mereo BioPharma
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mereo BioPharma (MREO)?
Mereo BioPharma (MREO) most recently closed at 0.31 USD, a +2.42% move versus the previous session.
What is the market cap of Mereo BioPharma (MREO)?
Mereo BioPharma currently has a market capitalization of 54.2M USD on BioPharmSignal.
What does Mereo BioPharma do?
Mereo BioPharma is a rare-disease and immunology company focused on precision therapies for underserved conditions. Its business is built around a concentrated pipeline and value creation through clinical execution.
On which exchange is MREO stock listed?
Mereo BioPharma (MREO) is associated with NASDAQ, United Kingdom, Biopharma.
What is setrusumab?
Mereo’s catalysts are setrusumab and the osteogenesis imperfecta program, plus any rare-disease update that extends the platform.
Which conditions is Mereo BioPharma targeting with setrusumab?
Mereo BioPharma is associated with immunology based on its company overview and current catalyst commentary.
How does Mereo BioPharma describe recent progress with setrusumab?
Mereo’s catalysts are setrusumab and the osteogenesis imperfecta program, plus any rare-disease update that extends the platform.
What is Mereo?
Mereo BioPharma is a rare-disease and immunology company focused on precision therapies for underserved conditions.